Semos Pharmaceuticals PVT LTD
Private pharmaceutical manufacturer · Karachi · Pakistan
Karachi pharmaceutical manufacturer producing oral, injectable and topical dosage forms for domestic and export markets.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Semos Pharmaceuticals (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- Plot No. 11, Sector 12-A, North Karachi Industrial Area, Karachi 75850, Pakistan · 75850
- Website
- semospharma.com ↗
- Phone
- +92 21 34688691
- info@semospharma.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Abex | Ceftriaxone | 250 mg | Dry powder for injection | 1 Vial | 076797 | PKR 208.60 | PKR 208.60/vial/unit | Near median |
| Abex | Ceftriaxone | 500 mg | Dry powder for injection | 1 Vial | 076798 | PKR 351.10 | PKR 351.10/vial/unit | 9% above median |
| Abex | Ceftriaxone | 1 g | Dry powder for injection | 1 Vial | 076799 | PKR 662.96 | PKR 662.96/vial/unit | 6% above median |
| Abex | Ceftriaxone | 250 mg | Injection | 1 Vial | 076800 | PKR 208.60 | PKR 208.60/vial/unit | 9% above median |
| Abex | Ceftriaxone | 2 g | IV injection | 1's | 086072 | PKR 873.16 | PKR 873.16/vial/unit | Near median |
| Abex | Ceftriaxone | 500 mg | Injection | 1's | 086073 | PKR 346.15 | PKR 346.15/vial/unit | 6% above median |
| Abex | Ceftriaxone | 1 g | IM injection | 1's | 086074 | PKR 653.59 | PKR 653.59/vial/unit | Near median |
| Abzid | Ceftazidime | 1 g | Dry powder for injection | 1 Vial | 079905 | PKR 456.99 | PKR 456.99/vial/unit | Near median |
| Abzid | Ceftazidime | 500 mg | Dry powder for injection | 1's | 082294 | PKR 243.30 | PKR 243.30/vial/unit | Near median |
| Abzid | Ceftazidime | 250 mg | IV injection | 1's | 086755 | PKR 159.95 | PKR 159.95/vial/unit | 15% above median |
| Arorx | Artesunate | 30 mg | Injection | 1's | 123126 | PKR 148.70 | PKR 148.70/vial/unit | Near median |
| Arorx | Artesunate | 120 mg | Injection | 1's | 123127 | PKR 413.06 | PKR 413.06/vial/unit | Near median |
| Arorx | Artesunate | 60 mg | Injection | 1's | 123128 | PKR 247.84 | PKR 247.84/vial/unit | Near median |
| Azicure | Azithromycin | 200 mg/5 mL | Suspension | 30ml | 028200 | PKR 647.67 | PKR 21.59/mL | Near median |
| Azicure | Azithromycin | 200 mg/5 mL | Suspension | 15ml | 028200 | PKR 330.45 | PKR 22.03/mL | Near median |
| Azicure | Azithromycin | 250 mg | Capsule | 6's | 028201 | PKR 268.49 | PKR 44.75/capsule | 10% below median |
| Azicure | Azithromycin | 500 mg | Tablet | 6's | 086756 | PKR 559.95 | PKR 93.33/tablet | 10% above median |
| Chloroquine Semos | Chloroquine | 250 mg | Tablet | 50x10's | 104122 | PKR 1,539.41 | PKR 3.08/tablet | 99% above median |
| Chloroquine Semos | Chloroquine | 50 mg/5 mL | Syrup | 60ml | 104123 | PKR 14.42 | PKR 0.24/mL | 29% below median |
| Clarithromycin Semos | Clarithromycin | 250 mg | Tablet | 10's | 104185 | PKR 371.54 | PKR 37.15/tablet | 22% below median |
| Clarithromycin Semos | Clarithromycin | 500 mg | Tablet | 10's | 104186 | PKR 619.24 | PKR 61.92/tablet | 26% below median |
| Clarithromycin Semos | Clarithromycin | 125 mg/5 mL | Dry suspension | 60ml | 104187 | PKR 345.22 | PKR 5.75/mL | 21% below median |
| Clarithromycin Semos | Clarithromycin | 250 mg/5 mL | Dry suspension | 60ml | 104188 | PKR 569.70 | PKR 9.50/mL | 18% below median |
| Demoxin | Doxycycline | 100 mg | Capsule | 3x10's | 028202 | PKR 275.53 | PKR 9.18/capsule | 17% above median |
| Efsan | Ciprofloxacin | 250 mg | Tablet | 10's | 074904 | PKR 247.84 | PKR 24.78/tablet | Near median |
| Efsan | Ciprofloxacin | 500 mg | Tablet | 10's | 074905 | PKR 444.04 | PKR 44.40/tablet | Near median |
| Falcither | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16's | 055880 | PKR 660.90 | PKR 41.31/tablet | 5% above median |
| Falcither | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 8's | 066954 | PKR 545.24 | PKR 68.16/tablet | 6% above median |
| Falcither | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 6's | 066955 | PKR 681.55 | PKR 113.59/tablet | Near median |
| Hydroxychloroquine | Hydroxychloroquine | 200 mg | Tablet | 5x10's | 104121 | PKR 731.06 | PKR 14.62/tablet | Near median |
| Iloz | Linezolid | 400 mg | Tablet | 12's | 104165 | PKR 2,371.87 | PKR 197.66/tablet | 16% below median |
| Iloz | Linezolid | 600 mg | Tablet | 12's | 104166 | PKR 4,152.40 | PKR 346.03/tablet | 12% below median |
| Iloz | Linezolid | 100 mg/5 mL | Dry suspension | 60ml | 104167 | PKR 568.60 | PKR 9.48/mL | 12% below median |
| Iloz | Linezolid | 100 mg/5 mL | Dry suspension | 120ml | 104167 | PKR 1,080.34 | PKR 9.00/mL | 16% below median |
| Iloz | Linezolid | 200 mg/100 mL | IV infusion | 100ml (Vial) | 127984 | PKR 410.39 | PKR 4.10/mL | 41% below median |
| Imbera | Artemether | 80 mg/mL | Injection | 1ml X 5's (Ampoules) | 120039 | PKR 728.78 | — | No comparator |
| Iverest | Ivermectin | 6 mg | Tablet | 20's | 076032 | PKR 1,032.65 | PKR 51.63/tablet | 6% below median |
| Moslve | Levofloxacin | 250 mg | Tablet | 10's | 058615 | PKR 516.33 | PKR 51.63/tablet | 8% above median |
| Moslve | Levofloxacin | 500 mg | Tablet | 10's | 058616 | PKR 859.17 | PKR 85.92/tablet | 9% above median |
| Permilot Lotion | Permethrin | 5 % | Lotion | 60ml | 076033 | PKR 157.27 | PKR 2.62/mL | Near median |
| Seaxim | Cefixime | 400 mg | Capsule | 5's | 057779 | PKR 592.04 | PKR 118.41/capsule | Near median |
| Seaxime Dry | Cefixime | 100 mg/5 mL | Dry suspension | 30ml | 057780 | PKR 330.39 | PKR 11.01/mL | 5% above median |
| Seaxime DS Dry | Cefixime | 200 mg/5 mL | Dry suspension | 30ml | 057781 | PKR 404.32 | PKR 13.48/mL | Near median |
| Sefox | Cefotaxime | 1 g | Dry powder for injection | 1Vial | 079902 | PKR 300.58 | PKR 300.58/vial/unit | Near median |
| Sefox | Cefotaxime | 250 mg | Dry powder for IV/IM injection | 1's | 082292 | PKR 110.89 | PKR 110.89/vial/unit | 8% above median |
| Sefox | Cefotaxime | 250 mg | Dry powder for injection | 1's | 082292 | PKR 110.89 | PKR 110.89/vial/unit | Near median |
| Sefox | Cefotaxime | 500 mg | Dry powder for injection | 1's | 082293 | PKR 167.12 | PKR 167.12/vial/unit | Near median |
| Selexin | Cephalexin | 250 mg | Capsule | 12's | 076790 | PKR 200.74 | PKR 16.73/capsule | 9% above median |
| Selexin | Cephalexin | 500 mg | Capsule | 12's | 076791 | PKR 393.62 | PKR 32.80/capsule | 7% above median |
| Selexin | Cephalexin | 125 mg/5 mL | Suspension | 60ml | 076792 | PKR 116.12 | PKR 1.94/mL | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.